Patents by Inventor Margarita Gekkieva

Margarita Gekkieva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20240052024
    Abstract: A method is provided for treating a patient having a neovascular ocular disease.
    Type: Application
    Filed: September 11, 2020
    Publication date: February 15, 2024
    Inventors: Margarita Gekkieva, Philippe Maria Clotaire Margaron
  • METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20210340242
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Methods for treating ocular diseases with brolucizumab
    Patent number: 11098110
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 24, 2021
    Assignee: NOVARTIS AG
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20180298092
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Applicant: Novartis AG
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Methods for treating neovascular age-related macular degeneration
    Patent number: 10035850
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 31, 2018
    Assignee: Novartis Pharma AG
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20160130337
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger